Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, ...

USFDA approved affordable biosimilars Bosaya and Aukelso approved by Biocon Biologics Ltd, offering treatment options for ...

Biocon Biologics is strengthening its US presence with multiple FDA approvals, a growing product portfolio, and a strong launch pipeline. MD & CEO Shreehas Tambe highlighted durable pricing, ...

Shares of the company ended 1.6% lower at a price of ₹354.40 on the BSE. Last week's losses have dragged the stock 4% lower ...

Biocon Biologics secures USFDA approval for two denosumab biosimilars (Prolia/Xtiva), targeting $5B US market for osteoporosis/bone metastasis. CEO Siddharth Mitta eyes $200M+ revenue contribution by ...

SEBI dismissed allegations of stock manipulation made by U.S. short-seller Hindenburg Research against the Adani Group. SEBI ...

Biocon CEO Siddharth Mittal reveals plans to launch generic versions of diabetes drug Ozempic in key markets by the end of ...

Biocon Ltd on Thursday said it has inaugurated its first manufacturing facility in the US, located in Cranbury, New Jersey.

Shares of Biocon Ltd rose 2% to Rs 361.25 on the BSE after its subsidiary, Biocon Biologics, received U.S. FDA approval for ...

YES Bank, Indosolar, JSW Steel, LTIMindtree, Hyundai Motor, Cochin Shipyard and Biocon are among the stocks to watch today, ...

With the stock's last traded price at Rs 360.20, Biocon has shown positive movement amid high trading volumes in Thursday's ...